Fluocinolone Acetonide
drug drugOn this page
Also known as Acetonide de fluocinoloneAcetonido de fluocinolonaCapexDerma-smoothe/fsDermoticFlucinolone acetonideFluocetFluocinolide (acetate)FluocinoloneFluonidFluotrexFs shampooIluvienNSC-92339Oto-synalarRetisertSynalarSynalar fteSynalar-c
Summary
Fluocinolone Acetonide (CHEMBL989) is an approved small-molecule anti-inflammatory drug (ATC S01BA15) targeting NR3C1; indicated across 17 conditions including eye disorder and uveitis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: S01BA15 (+3 more)
- Targets: 1 (NR3C1)
- Indications: 17 conditions
- Clinical trials: 27
- Chemistry: 452.5 Da · C24H30F2O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL989 |
| Name | Fluocinolone Acetonide |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6215 |
| ChEBI | CHEBI:31623 |
| ATC | S01BA15, S02BA08, D07AC04, C05AA10 |
| Molecular formula | C24H30F2O6 |
| Molecular weight | 452.5 |
| InChIKey | FEBLZLNTKCEFIT-VSXGLTOVSA-N |
SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O
IUPAC name: (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
ChEBI definition: A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.
Pharmacological roles (ChEBI): anti-inflammatory drug, antipruritic drug.
Also known as: Acetonide de fluocinolone, Acetonido de fluocinolona, Capex, Derma-smoothe/fs, Dermotic, Flucinolone acetonide, Fluocet, Fluocinolide (acetate), Fluocinolone, Fluocinolone acetonide, Fluonid, Fluotrex
Patent coverage: 9,504 distinct patent families (30,570 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | Agonist | 8.5 | 0.9% | P04150 |
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Lysine-specific demethylase 4E, Prelamin-A/C, Androgen receptor, Glucocorticoid receptor, Progesterone receptor, Mitogen-activated protein kinase 1, Hypoxia-inducible factor 1-alpha.
Bioactivity
ChEMBL activities: 7 potent at pChembl ≥ 5 of 9 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| HIF1A | 8.89 | Potency | 1.3 | nM | CHEMBL_ACT_4132662 |
| HIF1A | 8.89 | Potency | 1.3 | nM | CHEMBL_ACT_4519431 |
| NR3C1 | 8.85 | Ki | 1.42 | nM | CHEMBL_ACT_7644318 |
| NR3C1 | 8.5 | IC50 | 3.13 | nM | CHEMBL_ACT_7644317 |
| PGR | 7.97 | AC50 | 10.7 | nM | CHEMBL_ACT_25204024 |
| MAPK1 | 5.5 | Potency | 3162 | nM | CHEMBL_ACT_4737562 |
| AR | 5.27 | AC50 | 5382 | nM | CHEMBL_ACT_25203091 |
Target pathways
Aggregated over 1 target gene(s): NR3C1.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 1 | NR3C1 |
| Nuclear Receptor transcription pathway | 1 | NR3C1 |
| SUMOylation of intracellular receptors | 1 | NR3C1 |
| PTK6 Expression | 1 | NR3C1 |
| Regulation of RUNX2 expression and activity | 1 | NR3C1 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 1 | NR3C1 |
| Potential therapeutics for SARS | 1 | NR3C1 |
| Regulation of NPAS4 gene transcription | 1 | NR3C1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| negative regulation of transcription by RNA polymerase II | 1 |
| regulation of gluconeogenesis | 1 |
| chromatin organization | 1 |
| regulation of DNA-templated transcription | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| apoptotic process | 1 |
| chromosome segregation | 1 |
| signal transduction | 1 |
| glucocorticoid metabolic process | 1 |
| response to wounding | 1 |
| gene expression | 1 |
| microglia differentiation | 1 |
| adrenal gland development | 1 |
| nuclear receptor-mediated steroid hormone signaling pathway | 1 |
| regulation of glucocorticoid biosynthetic process | 1 |
Indications & clinical
Indications
8 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| eye disorder | 4 | MONDO:0005328 | EFO:0005752 |
| uveitis | 4 | MONDO:0020283 | EFO:1001231 |
| hemorrhoid | 4 | MONDO:0004872 | EFO:0009552 |
| atopic eczema | 4 | MONDO:0004980 | EFO:0000274 |
| psoriasis | 4 | MONDO:0005083 | EFO:0000676 |
| skin disorder | 4 | MONDO:0005093 | EFO:0000701 |
| infectious disease | 4 | MONDO:0005550 | EFO:0005741 |
| seborrheic dermatitis | 4 | MONDO:0006608 | EFO:1000764 |
6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| posterior uveitis | 3 | MONDO:0006918 | EFO:1001119 |
| anterior uveitis | 3 | MONDO:0006651 | EFO:1000811 |
| intermediate uveitis | 3 | MONDO:0006806 | EFO:1000986 |
| age-related macular degeneration | 2 | MONDO:0005150 | EFO:0001365 |
| retinal disorder | 2 | MONDO:0005283 | EFO:0003839 |
| macular degeneration | 2 | MONDO:0003004 | EFO:0009606 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 27.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 8 |
| Not specified | 6 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE2/PHASE3 | 3 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06539481 | PHASE4 | RECRUITING | Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye. |
| NCT00469183 | PHASE4 | COMPLETED | Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma |
| NCT00472966 | PHASE4 | COMPLETED | Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma |
| NCT00669071 | PHASE4 | TERMINATED | Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma |
| NCT00720928 | PHASE4 | UNKNOWN | Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet’s Disease |
| NCT02359526 | PHASE4 | COMPLETED | A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients |
| NCT02424019 | PHASE4 | COMPLETED | Phase 4 IOP Signals Associated With ILUVIEN® |
| NCT02472366 | PHASE4 | COMPLETED | A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy |
| NCT05844982 | PHASE3 | RECRUITING | Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy |
| NCT00344968 | PHASE3 | COMPLETED | Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema |
| NCT00407082 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants |
| NCT00456482 | PHASE2/PHASE3 | TERMINATED | Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant |
| NCT00490815 | PHASE3 | COMPLETED | Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema |
| NCT00502541 | PHASE2/PHASE3 | COMPLETED | Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema |
| NCT01304706 | PHASE3 | COMPLETED | Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study |
| NCT00032396 | PHASE2 | UNKNOWN | A Study to Evaluate Retisert in the Treatment of Patients With the Wet Form of Age-Related Macular Degeneration |
| NCT00605423 | PHASE2 | COMPLETED | The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot |
| NCT00695318 | PHASE2 | TERMINATED | Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy |
| NCT00770770 | PHASE2 | TERMINATED | Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina |
| NCT00008515 | PHASE1 | COMPLETED | Fluocinolone Implant to Treat Macular Degeneration |
| NCT01781936 | PHASE1 | COMPLETED | Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis |
| NCT05592717 | Not specified | RECRUITING | A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis |
| NCT01060787 | Not specified | COMPLETED | Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant |
| NCT01743690 | Not specified | COMPLETED | The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus |
| NCT03145025 | Not specified | COMPLETED | Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant |
| NCT04340505 | Not specified | COMPLETED | Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant |
| NCT07345507 | Not specified | COMPLETED | Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
173 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| FULVESTRANT | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| PODOFILOX | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| REGORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| ACENOCOUMAROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ALCLOMETASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| AMCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| APREPITANT | ChEMBL | Phase 4 (approved) | NR3C1 |
| AURANOFIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BECLOMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BENZBROMARONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE PHOSPHORIC ACID | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE VALERATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BUDESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BUTOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| CANRENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CHLORMADINONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CICLESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOBETASOL PROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOFAZIMINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DANAZOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEFLAZACORT | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOGESTREL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOXIMETASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOXYCORTICOSTERONE PIVALATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEXAMETHASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEXTROTHYROXINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIENESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIFLORASONE DIACETATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DOXORUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| DROSPIRENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| EFAVIRENZ | ChEMBL | Phase 4 (approved) | NR3C1 |
| ENZALUTAMIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| EPLERENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ESTRADIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ESTRIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ETHINYL ESTRADIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| EXEMESTANE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FELODIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUDROCORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUNISOLIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOROMETHOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOXYMESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLURANDRENOLIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUTICASONE FUROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUTICASONE PROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| GLUCAGON | ChEMBL | Phase 4 (approved) | NR3C1 |
| HALCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROCORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROCORTISONE BUTYRATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROXOCOBALAMIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROXYPROGESTERONE CAPROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| IDARUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| ISOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ISRADIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| KETOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| LASOFOXIFENE | ChEMBL | Phase 4 (approved) | NR3C1 |
| LOTEPREDNOL ETABONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MASOPROCOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEDROXYPROGESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEDRYSONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEGESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MESTRANOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLPREDNISOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLPREDNISOLONE HEMISUCCINATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLTESTOSTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METOPROLOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MIFEPRISTONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MITOTANE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MOMETASONE FUROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MONTELUKAST | ChEMBL | Phase 4 (approved) | NR3C1 |
| NAFTOPIDIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| NIMODIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NISOLDIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NOMEGESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORETHINDRONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORGESTIMATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORGESTREL | ChEMBL | Phase 4 (approved) | NR3C1 |
| OXYMETHOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PONATINIB | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNICARBATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNISOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PROGESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| QUINESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| RACECADOTRIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| RIBOFLAVIN 5’-PHOSPHATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| RIMEXOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
Related Atlas pages
- Genes: NR3C1
- Indicated for: eye disorder, uveitis, hemorrhoid, atopic eczema, psoriasis, skin disorder, infectious disease, seborrheic dermatitis
- In clinical trials for: posterior uveitis, anterior uveitis, intermediate uveitis, age-related macular degeneration, retinal disorder, macular degeneration
- Drugs: Fulvestrant, Podofilox, Regorafenib, Acenocoumarol, Alclometasone Dipropionate, Amcinonide, Amiodarone, Aprepitant, Auranofin, Bazedoxifene, Beclomethasone Dipropionate, Benzbromarone, Betamethasone, Betamethasone Dipropionate, Betamethasone Phosphoric Acid, Betamethasone Valerate, Budesonide, Butoconazole, Candesartan Cilexetil, Canrenone, Chlormadinone, Ciclesonide, Clobetasol Propionate, Clofazimine, Clotrimazole, Cortisone, Danazol, Daunorubicin, Deflazacort, Desogestrel, Desonide, Desoximetasone, Desoxycorticosterone Pivalate, Dexamethasone, Dextrothyroxine, Dienestrol, Diethylstilbestrol, Diflorasone Diacetate, Doxorubicin, Drospirenone, Econazole, Efavirenz, Enzalutamide, Eplerenone, Estradiol, Estriol, Ethinyl Estradiol, Exemestane, Felodipine, Fludrocortisone, Flunisolide, Fluocinonide, Fluorometholone, Fluoxymesterone, Flurandrenolide, Fluticasone Furoate, Fluticasone Propionate, Glucagon, Halcinonide, Hydrocortisone, Hydrocortisone Butyrate, Hydroxocobalamin, Hydroxyprogesterone Caproate, Idarubicin, Isoconazole, Isradipine, Ketoconazole, Lasofoxifene, Loteprednol Etabonate, Masoprocol, Medroxyprogesterone, Medrysone, Megestrol, Mestranol, Methylprednisolone, Methylprednisolone Hemisuccinate, Methyltestosterone, Metoprolol, Mifepristone, Mitotane, Mometasone Furoate, Montelukast, Naftopidil, Nimodipine, Nisoldipine, Norethindrone, Norgestimate, Norgestrel, Oxymetholone, Ponatinib, Prednicarbate, Prednisolone, Prednisone, Progesterone, Quinestrol, Racecadotril, RIBOFLAVIN 5’-PHOSPHATE, Rimexolone